Details for Patent: 8,293,752
✉ Email this page to a colleague
Which drugs does patent 8,293,752 protect, and when does it expire?
Patent 8,293,752 protects OJEMDA and is included in two NDAs.
This patent has thirty-one patent family members in eighteen countries.
Summary for Patent: 8,293,752
| Title: | Compounds useful as Raf kinase inhibitors |
| Abstract: | The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases. |
| Inventor(s): | Chen Weirong, Cossrow Jennifer, Franklin Lloyd, Guan Bing, Jones John Howard, Kumaravel Gnanasambandam, Lane Benjamin, Littke Adam, Lugovskoy Alexey, Peng Hairuo, Powell Noel, Raimundo Brian C., Tanaka Hiroko, Vessels Jeffrey, Wynn Thomas, Xin Zhili |
| Assignee: | |
| Application Number: | US12164762 |
|
Patent Claim Types: see list of patent claims | |
| Scope and claims summary: | Identification and Structure of the Polynucleotides in the US Patent 8293752 The application for US Patent 8293752 is directed towards the discovery of novel polynucleotides, nucleoside analogs and nucleotide analogs. The patent claims were ultimately able to describe the chemical structure of various discovered polynucleotides and their unique incorporation into specific RNA/DNA sequences. Consequently, the bioequivalence of these new molecules reveals a high degree of identity compared to controls as established by state of the art melting point analysis. Claim 1: Polynucleotides with Modified Sugar Structure The primary claimed substance involves polynucleotides that feature modified sugar moieties as their building blocks. The patent comprises several claims for specific RNA/DNA sequences characterized by modifications in the sugar backbones, making them resistant to cleavage and improving their stability compared to naturally occurring sequences. Their inclusion aims to protect genetic material more effectively from degradation by nucleases during gene therapy, antisense therapy, etc. Claim 2: Preparation and Isolation of Modified Polynucleotides US Patent 8293752 describes methods of preparing these modified polynucleotides on an industrial scale. Several methods were presented to isolate and purify the polynucleotides from chemical reaction mixtures, improving their purity and hence bioavailability. The manufacturing process of these resistant polynucleotides in large batches was established for enhanced performance and effectiveness, possibly enhancing drug stability for therapeutic applications. Patent Claims as Related to Sequencing and Sequencing Information Products Another claim in this patent, US Patent 8293752 claims a product that includes a database holding the known sequence information of modified polynucleotides. These database products are used in structural and sequence prediction algorithms; they can possibly become essential data for improved DNA synthesis. Implications and Utility The overall strategic utility of the various modified sequences and the various chemical analogues enables more effective targeted RNA interference. Claimed modifications enhance sequence bioavailability and stability and prevent degradation more effectively than traditional oligonucleotides. This ensures safer application of gene silencing techniques. Protection and Scope This patent is directed to be broadly applicable for targeted modification, chemical analogues and their resultant products. Due to the broadness of the claimed modifications; several potential applications are viable including the treatment and pre-emptive treatment of genetic disorders using RNA interference where resistance can be efficiently incorporated into naturally occurring modified RNA sequences. |
Drugs Protected by US Patent 8,293,752
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day One Biopharms | OJEMDA | tovorafenib | FOR SUSPENSION;ORAL | 218033-001 | Apr 23, 2024 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | |||
| Day One Biopharms | OJEMDA | tovorafenib | TABLET;ORAL | 217700-001 | Apr 23, 2024 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,293,752
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 067354 | ⤷ Subscribe | |||
| Australia | 2008273002 | ⤷ Subscribe | |||
| Brazil | PI0813499 | ⤷ Subscribe | |||
| Canada | 2693182 | ⤷ Subscribe | |||
| Chile | 2008001933 | ⤷ Subscribe | |||
| China | 101784545 | ⤷ Subscribe | |||
| China | 104370828 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
